Goldman Sachs Maintains Buy on Versigent, Lowers Price Target to $58
Goldman Sachs analyst Mark Delaney maintains Versigent (NYSE:VGNT) with a Buy and lowers the price target from $59 to $58.
Stocks · News reference
Versigent Q2 2026 Earnings Call Transcript
Versigent (NYSE:VGNT) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts and
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
David Einhorn Has 7 New Stock Picks: Hedge Fund Manager Bets on Buyouts, Spinoffs
A hedge fund is betting on spinoffs and buyouts for several of its new portfolio holdings.
Argus Research Maintains Buy on Versigent, Raises Price Target to $54
Argus Research analyst Bill Selesky maintains Versigent (NYSE:VGNT) with a Buy and raises the price target from $50 to $54.